Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q1 FY2022 Earnings Presentation
21 slides from Cohance Lifesciences's earnings presentation, Aug 16, 2021
Slide 1: Suven Pharma Earnings Presentation Q1FY22
SUVEN PHARMA Earnings Presentation Q1FY22
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 11 Table of Operation & Financial Company Background Contents Performance Q1FY22 3
Slide 4: Operation & Financial Performance Q1FY22
Operation & Financial Performance Q1FY22 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other Ser vices 153.39 93.51 25.54 84.87 124.88 19.84 Q1FY21 Q1FY22 Q1FY21 Q1FY22 Q1FY21 Q1FY22 Note: Figures in Rs. Crore 5
Slide 6: Financial Snapshot Q1FY22
Financial Snapshot Q1FY22 Growth in Growth in Growth in Revenue EBITDA PAT 2.71% 24.13% 26.36% 6
Slide 7: Key Ratios Q1FY22
Key Ratios Q1FY22 EBIT to EBITDA to PAT to Income Income Income 41.33% 44.66% 30.21% 7
Slide 8: Financials Q1FY22
Financials Q1FY22 Revenue EBIDTA PAT EPS 2,696 812 814 3.2 3.2 2,625 1,204 2,440 1,174 645 2.5 970 RUPEES MN RUPEES MN RUPEES MN RUPEES Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 8
Slide 9: Financials Q1FY22 – EBITDA and PAT Margin
Financials Q1FY22 EBITDA Margin (%) PAT Margin (%) 45% 38% 37% 33% 30% 25% Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 9
Slide 10: Financial Table – Q1 FY22
Financial Table – Q1 FY22 Quarter ended 30-Jun-21 31-Mar-21 30-Jun-20 Revenue 2,695.84 2,624.63 2,439.72 EBITDA 1,203.99 969.91 1,173.60 EBITDA Margin 44.66% 36.95% 48.10% EBIT 1,114.06 886.76 1,102.97 EBIT Margin 41.33% 33.79% 45.21% Finance costs 21.26 18.70 27.20 Depreciation 89.93 83.15 70.63 Ta
Slide 11: Company Background
Company Background PHARMA
Slide 12: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 12
Slide 13: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBIT and PAT process research & across the entire CDMO of Rs 26,958 lacs, Rs 11,140 lacs and
Slide 14: Suven is an integrated Contract Development and Manufacturing Operations company
Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since our founding in
Slide 15: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 15 15
Slide 16: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 16
Slide 17: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities Present across the research capabilities to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 17
Slide 18: Business Drivers
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply research skills Repeat business with the launch of owing to long product by global st
Slide 19: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 20: Contact
Contact For queries and requests, please contact: Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: info@suvenpharm.com For more info: www.suvenpharm.com # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. Gavin Desa / Risha
Slide 21: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — Q1 FY2022 Earnings Presentation on 6ix